Tideglusib - AMO Pharma

Drug Profile

Tideglusib - AMO Pharma

Alternative Names: AMO-02; NP-031112; NP-12; Nypta; Zentylor

Latest Information Update: 02 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuropharma
  • Developer AMO Pharma; Noscira
  • Class Antidementias; Small molecules; Thiadiazoles
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myotonic dystrophy; Progressive supranuclear palsy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Autistic disorder; Myotonic dystrophy
  • Discontinued Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 29 Oct 2018 Phase-II clinical trials in Autistic disorder (In adolescents) in Canada (PO) before October 2018
  • 29 Oct 2018 Positive efficacy and adverse events data from the phase II TIDE trial in Autistic disorder released by AMO Pharma
  • 29 Oct 2018 AMO Pharma completes the phase II TIDE trial in Autistic disorder (In adolescents) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top